SavedAdd your journal

Journals / International Journal of Nature and Life Sciences / 2021 / Cilt: 5 - Sayı: 1

Evaluation of MMP2, Caspase-3 and C-Kit Expression on Thyroid Papillary Cancer Prognosis

Arzu BOZTAŞ
Hakan BULUŞ
Gülçin GÜLER ŞİMŞEK
Altan AYDIN
Arzu KOÇDOĞAN
Volkan ATEŞ
Serpil OĞUZTÜZÜN
Pages
23–32
Publication Date
2021-06-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Clinicopathological parameters were thought to be more important than c-kit, caspase 3 and MMP2 in predicting prognosis in thyroid papillary cancers.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A number of new molecular and genetic factors are currently being studied in determining the prognosis of thyroid papillary carcinoma.
📊
Key Findings & Data:In our study, we aimed to determine if there was a relationship between prognostic factors and expression of Matrixmatalloproteniase 2 (MMP-2), the tyrosine-kinase receptor CD117 (c-kit) and caspase-3.
💡
Conclusion & Impact:Clinicopathological parameters were thought to be more important than c-kit, caspase 3 and MMP2 in predicting prognosis in thyroid papillary cancers.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Thyroid papillary carcinoma · MMP-2 · C-kit

Abstract

A number of new molecular and genetic factors are currently being studied in determining the prognosis of thyroid papillary carcinoma. In our study, we aimed to determine if there was a relationship between prognostic factors and expression of Matrixmatalloproteniase 2 (MMP-2), the tyrosine-kinase receptor CD117 (c-kit) and caspase-3. MMP2, c-kit and caspase-3 by immunohistochemical (IHC) method were studied in both intact and pathological tissue of the thyroid gland removed after surgery in patients with thyroid papillary cancer. Prognostic factors such as age, histological stage, extrathyroidal spread, metastasis, tumor size were also evaluated. There was no statistically significant difference between prognosis and c-kit, MMP-2 and caspase-3 expression in patients (p>0.05). Clinicopathological parameters were thought to be more important than c-kit, caspase 3 and MMP2 in predicting prognosis in thyroid papillary cancers.

🔖

Cite This Article

BOZTAŞ, A., BULUŞ, H., ŞİMŞEK, G. G., AYDIN, A., KOÇDOĞAN, A., ATEŞ, V., OĞUZTÜZÜN, S. (2021). Evaluation of MMP2, Caspase-3 and C-Kit Expression on Thyroid Papillary Cancer Prognosis. International Journal of Nature and Life Sciences, Cilt: 5 - Sayı: 1, 23–32. https://ajindex.com/articles/767942

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Aliustaoğlu, M. (2009). Temel kanser fizyopatolojisi. Klinik Gelişim, 22(3), 46-49.
  2. Amelina, C., Caruntu, I. D., Gıuşca, S. E., & Balan, R. A. (2010). Matrix metalloproteinases involvement in pathologic conditions. Romanian Journal of Morphology and Embryology, 51(2), 215–228.
  3. Apakkan Aksun, S., Bayındır, O., & Özmen, D. (2001). Metalloproteinazlar, inhibitörleri ve ilişkili fizyolojik ve patolojik durumlar. Türkiye Klinikleri Tıp Bilimleri, 21, 332–342.
  4. Aydın, O., Yıldız, L., Kefeli, M., Yüksel, C., Süllü, Y. (2006). Tiroid papiller karsinomlarda c-kit. Türk Patoloji Dergisi, 22(1), 17-20.
  5. Campo, E., Maria, J., Merino, J., Liotta, L., Neumann, R., & Stetler-Stevenson, W. G. (1992). Distribution of the 72-kDa type IV collagenase in non-neoplastic and neoplastic thyroid tissue. Human Pathology, 23, 1395–1401.
  6. Cho Mar, K., Eimoto, T., Tateyama, H., Arai, Y., Fujiyoshi Y., & Hamaguchi, M. (2006). Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions. Histopathology, 48, 286–294.
  7. Cvejic, D., Savin, S., Paunovic, I., Tatic, S., & Havelka, M. (2000) İmmunohistochemical localization of matrix metalloproteinase-2(MMP-2) in medullary thyroid carcinoma. Archive of Oncology, 8, 95-97.
  8. Franc, B. (2003). Observer variation of lesions of the thyroid. American Journal of Surgical Pathology, 27, 1177-1178.
  9. Hewitt, R., & Dan, K. (1996). Stromal cell expression of components of matrix degrading protease systems in human cancer. Enzyme Protein, 49,163–173.
  10. Kessenbrock, K., Plaks, V., & Werb, Z. (2010). Matrix Metalloproteinases: Regulators of the tumor microenvironment. Cell, 141(1), 52–67. https://doi.org/10.1016/j.cell.2010.03.015
  11. Koyun, E., Karadag, R., Ozkanli, S., Oguztuzun, S., Kocdogan, A. K., & Ozsoy, I. (2020) Caspase-3, p53 and Bcl-2 expression in basal cell carcinoma of the eyelid. Advances in Dermatology and Allergology, 37(4), 535–539.
  12. Liang, H., Zhong, Y., Luo, Z., Huang, Y., Lin, H., Luo, M., Zhan, S., Xie, K., Ma, Y., & Li, Q. Q. (2010). Assessment of biomarkers for clinical diagnosis of papillary thyroid carcinoma with distant metastasis. International Journal of Biological Markers, 25, 38–45.
  13. Maeta, H,, Ohgi, S., & Terada, S. (2001). Protein expression of matrixmetalloproteinase 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroidcarcinomas. Virchows Archiv, 438, 121–128.
  14. Matrisian, L. M. (1990). Metalloproteinases and the inhibitors in matrixremodeling. Trends in Genetics, 6(4), 121–125. Mishu